Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials
暂无分享,去创建一个
Matt Vassar | Cole Wayant | E. Turner | M. Vassar | C. Wayant | Chase Meyer | P. Sinnett | Erick Turner | Chase Meyer | Philip Sinnett
[1] A. Gafni,et al. Seeking a second opinion: do patients need a second opinion when practice guidelines exist? , 2007, Health policy.
[2] Vinay Prasad,et al. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. , 2015, JAMA oncology.
[3] V. Prasad,et al. Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. , 2017, The Hastings Center report.
[4] A. Lo,et al. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. , 2014, JAMA otolaryngology-- head & neck surgery.
[5] K. Malterud. Qualitative research: standards, challenges, and guidelines , 2001, The Lancet.
[6] Lisa Rosenbaum,et al. Beyond moral outrage--weighing the trade-offs of COI regulation. , 2015, The New England journal of medicine.
[7] M. Field,et al. Committee on Conflict of Interest in Medical Research, Education, and Practice , 2009 .
[8] T. Wiggers,et al. Discrepancy between second and first opinion in surgical oncological patients. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[9] K. Pienta,et al. Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests , 2017, JAMA oncology.